While reporting financial results for the third quarter on Wednesday, Biogen Inc. (BIIB) trimmed its earnings, adjusted earnings and revenue guidance for the full-year 2020, due to the impact of multiple generic entrants for its multiple sclerosis drug Tecfidera in the U.S.
from RTT - Earnings https://ift.tt/2IUVy61
via IFTTT
No comments:
Post a Comment